PLoS Pathogens (Jun 2021)

Sustained viremia suppression by SHIVSF162P3CN-recalled effector-memory CD8+ T cells after PD1-based vaccination.

  • Yik Chun Wong,
  • Wan Liu,
  • Lok Yan Yim,
  • Xin Li,
  • Hui Wang,
  • Ming Yue,
  • Mengyue Niu,
  • Lin Cheng,
  • Lijun Ling,
  • Yanhua Du,
  • Samantha M Y Chen,
  • Ka-Wai Cheung,
  • Haibo Wang,
  • Xian Tang,
  • Jiansong Tang,
  • Haoji Zhang,
  • Youqiang Song,
  • Lisa A Chakrabarti,
  • Zhiwei Chen

DOI
https://doi.org/10.1371/journal.ppat.1009647
Journal volume & issue
Vol. 17, no. 6
p. e1009647

Abstract

Read online

HIV-1 functional cure requires sustained viral suppression without antiretroviral therapy. While effector-memory CD8+ T lymphocytes are essential for viremia control, few vaccines elicit such cellular immunity that could be potently recalled upon viral infection. Here, we investigated a program death-1 (PD1)-based vaccine by fusion of simian immunodeficiency virus capsid antigen to soluble PD1. Homologous vaccinations suppressed setpoint viremia to undetectable levels in vaccinated macaques following a high-dose intravenous challenge by the pathogenic SHIVSF162P3CN. Poly-functional effector-memory CD8+ T cells were not only induced after vaccination, but were also recalled upon viral challenge for viremia control as determined by CD8 depletion. Vaccine-induced effector memory CD8+ subsets displayed high cytotoxicity-related genes by single-cell analysis. Vaccinees with sustained viremia suppression for over two years responded to boost vaccination without viral rebound. These results demonstrated that PD1-based vaccine-induced effector-memory CD8+ T cells were recalled by AIDS virus infection, providing a potential immunotherapy for functional cure.